<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331863</url>
  </required_header>
  <id_info>
    <org_study_id>P091203</org_study_id>
    <nct_id>NCT01331863</nct_id>
  </id_info>
  <brief_title>Airway and/or Pulmonary Vessels Transplantation</brief_title>
  <acronym>TRACHBRONCAR</acronym>
  <official_title>Replacement of the Airways and/or the Pulmonary Vessels Using a Cryopreserved Arterial Allograft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  First study (BRONC-ART) The purpose of this prospective study is to evaluate the 90-day&#xD;
           morbidity and mortality rates of bronchial transplantation using cryopreserved aortic&#xD;
           allograft in proximal lung cancer surgery. The investigators hypothesize that this stage&#xD;
           1-2 surgical innovation could be safe and effective in order to reduce the 90-day&#xD;
           morbidity and mortality rates compared to those observed with pneumonectomy, especially&#xD;
           when some factors are present: age &gt; 70 years, right side, neoadjuvant&#xD;
           chemoradiotherapy.&#xD;
&#xD;
        -  Current study (TRACHEO BRONC-ART) The BRONC-ART study was extended to major (malignant&#xD;
           or benign) lesions of the trachea requiring airway transplantation.&#xD;
&#xD;
      For these patients, resection followed by direct end to end anastomosis is not possible or at&#xD;
      high risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery remains the best option for curative treatment of early stages Non-Small Cell Lung&#xD;
      Cancer (NSCLC). Peripheral tumors are usually resected using lobectomy with a low 90-day&#xD;
      morbidity and mortality rate (2%). Central NSCLC often require a pneumonectomy with a high&#xD;
      90-day morbidity and mortality rate (up to 24%), especially when some factors are present:&#xD;
      age &gt; 70 years, right side, neoadjuvant chemoradiotherapy. On the other hand, bronchoplastic&#xD;
      lobectomies have been proposed in order to avoid pneumonectomy. However, more than fifty&#xD;
      years after their first description, bronchoplastic lobectomies remain uncommon (&lt;1% of all&#xD;
      pulmonary resection). This could be explained by some technical difficulties showing the&#xD;
      potential interest of a bronchial substitute. In a 10-year research phase on a sheep model&#xD;
      (n=108), we demonstrated that aortic grafts could be valuable substitutes for&#xD;
      tracheobronchial replacement. We observed a progressive transformation of the aortic tissue&#xD;
      into airway tissue comprising epithelium and regenerated cartilage. The technique was&#xD;
      extended to clinical tracheal replacement by us and others with encouraging results. We&#xD;
      proposed to evaluate the feasibility of the use of a stent-supported cryopreserved aortic&#xD;
      allograft as a bronchial substitute to prevent pneumonectomy and its associated high&#xD;
      mortality rate in NSCLC surgery. Primary outcome will be the 90-day mortality. Secondary&#xD;
      outcomes will be the postoperative complications, the 90-day morbidity. This prospective open&#xD;
      study will include 20 to 30 patients according to eligibility criteria (see below). The&#xD;
      operation will consist of the curative resection of the NSCLC followed by the replacement of&#xD;
      a bronchial segment using a cryopreserved allograft in order to re-implant a functional&#xD;
      pulmonary lobe. A stent will be placed in the graft to prevent airway collapse.&#xD;
&#xD;
      -Current study (TRACHEO BRONC-ART) The BRONC-ART study was extended to major (malignant or&#xD;
      benign) lesions of the trachea requiring airway transplantation. For these patients,&#xD;
      resection followed by direct end to end anastomosis is not possible or at high risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2011</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>90-day morbidity</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Tracheal Neoplasm</condition>
  <condition>Tracheal Stenosis</condition>
  <arm_group>
    <arm_group_label>single arm surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Airway and/or pulmonary Vessels Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Airway and/or pulmonary Vessels Transplantation</intervention_name>
    <description>Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY</description>
    <arm_group_label>single arm surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient age ≥18 years and patient capable of giving consent to the carrying out of a&#xD;
             medical research procedure&#xD;
&#xD;
          -  patient with proximal Lung Cancer (LC) requiring surgical resection (carinal&#xD;
             resection, pneumonectomy, bronchoplastic lobectomy) after neoadjuvant chemotherapy or&#xD;
             not and with adequate preoperative lung function tests&#xD;
&#xD;
          -  or patient with proximal LC requiring a pneumonectomy without adequate preoperative&#xD;
             lung function tests&#xD;
&#xD;
          -  patients with extended lesions malignant or benign of the trachea without bronchitic&#xD;
             lesion and who are in therapeutic impasse.&#xD;
&#xD;
          -  or patient older than 70 years with proximal LC requiring a pneumonectomy&#xD;
&#xD;
          -  decision made by a multidisciplinary team&#xD;
&#xD;
          -  patient information and consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient age &lt; 18 years or patient not capable of giving consent to the carrying out of&#xD;
             a medical research procedure&#xD;
&#xD;
          -  patient with proximal or peripheral LC requiring a simple lobectomy&#xD;
&#xD;
          -  patient with unresectable LC because of major local involvement, N3 and/or M1&#xD;
             status(with the exception of a unique resectable brain metastasis)&#xD;
&#xD;
          -  patient with tracheal lesion that can be isolated from a simple resection anastomosis&#xD;
             tracheal&#xD;
&#xD;
          -  iodine allergy&#xD;
&#xD;
          -  preoperative evaluation not allowing a simple lobectomy&#xD;
&#xD;
          -  patient not affiliated to the French Social Security System&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel MARTINOD, Pr, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, CHU Paris-Seine-Saint-Denis</name>
      <address>
        <city>Bobigny</city>
        <state>Seine-Saint-Denis</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchial disease</keyword>
  <keyword>Lung cancer surgery</keyword>
  <keyword>Aorta/aortic Allograft</keyword>
  <keyword>homograft</keyword>
  <keyword>Tracheal disease</keyword>
  <keyword>Benign</keyword>
  <keyword>Malignant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tracheal Neoplasms</mesh_term>
    <mesh_term>Tracheal Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

